The Role Of Real World Evidence To Support US FDA And TGA Registrations
Real world evidence (RWE) can contribute valuable information to new medicine registrations, in particular for diseases that are difficult to assess in randomized clinical trials (RCTs) and for emerging technologies such as gene and cell therapies to help enhance our understanding of such products.
Regulatory agencies worldwide are considering how they may incorporate RWE into their decision making processes for new medicine applications.
VIEW THE WHITE PAPER! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader X
Subscribe to Clinical Leader